First expirience of adalimumab administration in Russia: preliminary results of an open 24 week study
Introduction. Adalimumab (Humira) is a monoclonal anti-TNFa antibody fully identical to human antibodies, a member of group of TNFa blockers which are now the main biological drugs for the treatment of rheumatoid arthritis (RA). Till recently adalimumab was little known in Russia. Material and metho...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2008-10-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/554 |